Cargando…

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters

Background: Nonadherence to medication is prevalent in persons diagnosed with schizophrenia, thus increasing the likelihood of relapse, poor health outcomes, hospitalization, high treatment costs, and high rates of both violent and non-violent offenses. Objective: To assess the association between l...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatta, Madhav P., Bista, Saroj, El Khoury, Antoine C., Hutzell, Eric G., Tandon, Neeta, Smith, Douglas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137150/
https://www.ncbi.nlm.nih.gov/pubmed/34056030
http://dx.doi.org/10.36469/jheor.2021.22979
_version_ 1783695566703689728
author Bhatta, Madhav P.
Bista, Saroj
El Khoury, Antoine C.
Hutzell, Eric G.
Tandon, Neeta
Smith, Douglas
author_facet Bhatta, Madhav P.
Bista, Saroj
El Khoury, Antoine C.
Hutzell, Eric G.
Tandon, Neeta
Smith, Douglas
author_sort Bhatta, Madhav P.
collection PubMed
description Background: Nonadherence to medication is prevalent in persons diagnosed with schizophrenia, thus increasing the likelihood of relapse, poor health outcomes, hospitalization, high treatment costs, and high rates of both violent and non-violent offenses. Objective: To assess the association between long-acting injectable (LAI) antipsychotic use and criminal justice system encounters in patients with schizophrenia or schizoaffective disorder. Methods: This retrospective follow-up study was conducted among patients aged ≥18 years treated for schizophrenia or schizoaffective disorder at a community mental health center in Akron, Ohio, between January 1, 2010, and June 15, 2016. The incidence of criminal justice system encounters at 6 months, 1 year, and 2 years pre- versus post-LAI antipsychotic initiation was assessed. A subanalysis was conducted for individuals with a history of prior arrest. Results: Overall, the risk ratio (RR) of having an encounter with the criminal justice system was significantly lower for patients treated with LAI antipsychotics 1 year after initiation of treatment compared with a similar time period prior to initiation (RR [95% confidence interval (CI)]: 0.74 [0.59–0.93]; P<0.01) and 2 years (0.74 [0.62–0.88]; P<0.0001). Statistically significant reductions in criminal justice system encounters after treatment than before treatment were observed in the once-monthly paliperidone palmitate (PP1M) cohort. The incidence of arrests was lower in the 6-month (27 vs 85 arrests), 1-year (46 vs 132 arrests) and 2-year (88 vs 196 arrests) periods post-index LAI medication than in the corresponding periods pre-index LAI medication among individuals with a history of prior arrest. Conclusions: Patients with schizophrenia or schizoaffective disorder who were initiated on a LAI antipsychotic medication, specifically PP1M, were less likely to have an encounter with the criminal justice system compared with a similar time period before the initiation of LAI treatment.
format Online
Article
Text
id pubmed-8137150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Columbia Data Analytics, LLC
record_format MEDLINE/PubMed
spelling pubmed-81371502021-05-27 Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters Bhatta, Madhav P. Bista, Saroj El Khoury, Antoine C. Hutzell, Eric G. Tandon, Neeta Smith, Douglas J Health Econ Outcomes Res Neurological Diseases Background: Nonadherence to medication is prevalent in persons diagnosed with schizophrenia, thus increasing the likelihood of relapse, poor health outcomes, hospitalization, high treatment costs, and high rates of both violent and non-violent offenses. Objective: To assess the association between long-acting injectable (LAI) antipsychotic use and criminal justice system encounters in patients with schizophrenia or schizoaffective disorder. Methods: This retrospective follow-up study was conducted among patients aged ≥18 years treated for schizophrenia or schizoaffective disorder at a community mental health center in Akron, Ohio, between January 1, 2010, and June 15, 2016. The incidence of criminal justice system encounters at 6 months, 1 year, and 2 years pre- versus post-LAI antipsychotic initiation was assessed. A subanalysis was conducted for individuals with a history of prior arrest. Results: Overall, the risk ratio (RR) of having an encounter with the criminal justice system was significantly lower for patients treated with LAI antipsychotics 1 year after initiation of treatment compared with a similar time period prior to initiation (RR [95% confidence interval (CI)]: 0.74 [0.59–0.93]; P<0.01) and 2 years (0.74 [0.62–0.88]; P<0.0001). Statistically significant reductions in criminal justice system encounters after treatment than before treatment were observed in the once-monthly paliperidone palmitate (PP1M) cohort. The incidence of arrests was lower in the 6-month (27 vs 85 arrests), 1-year (46 vs 132 arrests) and 2-year (88 vs 196 arrests) periods post-index LAI medication than in the corresponding periods pre-index LAI medication among individuals with a history of prior arrest. Conclusions: Patients with schizophrenia or schizoaffective disorder who were initiated on a LAI antipsychotic medication, specifically PP1M, were less likely to have an encounter with the criminal justice system compared with a similar time period before the initiation of LAI treatment. Columbia Data Analytics, LLC 2021-05-19 /pmc/articles/PMC8137150/ /pubmed/34056030 http://dx.doi.org/10.36469/jheor.2021.22979 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurological Diseases
Bhatta, Madhav P.
Bista, Saroj
El Khoury, Antoine C.
Hutzell, Eric G.
Tandon, Neeta
Smith, Douglas
Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title_full Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title_fullStr Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title_full_unstemmed Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title_short Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
title_sort long-acting injectable antipsychotic use in patients with schizophrenia and criminal justice system encounters
topic Neurological Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137150/
https://www.ncbi.nlm.nih.gov/pubmed/34056030
http://dx.doi.org/10.36469/jheor.2021.22979
work_keys_str_mv AT bhattamadhavp longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters
AT bistasaroj longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters
AT elkhouryantoinec longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters
AT hutzellericg longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters
AT tandonneeta longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters
AT smithdouglas longactinginjectableantipsychoticuseinpatientswithschizophreniaandcriminaljusticesystemencounters